CMPX Historical PE Ratio Notes

— Compass Therapeutics (NASDAQ: CMPX) is a clinical-stage biotechnology company focused on the discovery & development of novel antibody therapeutics for cancer. The company's pipeline centers on targeting the tumor microenvironment, immune modulation, & other mechanisms to improve outcomes for patients not responding to current treatments. Because Compass does not yet have approved products generating significant revenue, its earnings have historically been negative. When you look at CMPX's historical price, earnings, & PE ratio data, you'll notice either a lack of meaningful PE values or very large, undefined, or “N/A” entries. This is typical for clinical-stage biotech companies, as the stock market cannot calculate a traditional price-to-earnings ratio without positive net earnings. As a result, investors in CMPX have historically valued the stock based more on its future prospects, pipeline advancement, & clinical trial results rather than current earnings. Comparing PE ratios over time for CMPX will likely show little relevance until the company begins to generate consistent, positive earnings from commercialized products. In short, understanding Compass Therapeutics' stage of development is key to interpreting the historical PE ratio data you are about to review.

On this page we presented the Compass Therapeutics Historical PE Ratio information for Compass Therapeutics' stock. The average CMPX historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average CMPX historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this CMPX historical PE result, against the recent PE: when this page was posted on 5/14/2026, the most recent closing price for CMPX had been 1.98, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on CMPX or any other given stock, valuation analysis for CMPX can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Compass Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for CMPX. Thanks for visiting, and the next time you need to research CMPX Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.